Dates: 10/7/24
HEADLINE: “TC BioPharm (NASDAQ:TCBP): Cancer Treatment Patent Issued!
Company Name: TC Biopharm
Ticker: TCBP
Exchange: NASDAQ
Preview of Small Cap Exclusive’s Research Report:
Update 10/3/24
Since we released this research report we have seen gains of almost 25%, congragulations to our subscribbers. Just yesterday investors had plenty of opportunities to get in to their position at around $5.20 and TCBP is currently trading at $6.40 representing $1.20 in gains or 23% gains. In a DAY!
BREAKING NEWS:
TC BioPharm (NASDAQ: TCBP) has announced a partnership with Carnegie Mellon University to develop an artificial intelligence solution for optimizing donor screening and matching processes in cell therapy. The company will collaborate with Dr. Wei Wu from the Ray and Stephanie Lane Computational Biology Department to leverage AI in addressing the ‘big data problem’ of donor variability and patient matching.
The initiative aims to enhance manufacturing yields, improve production processes, and potentially boost patient outcomes. Bryan Kobel, CEO of TC BioPharm, emphasized the significance of this partnership in advancing the cell therapy industry and addressing challenges beyond current HLA matching processes. Dr. Wu highlighted the potential of AI to transform precision medicine and personalized cell therapies.
TCBP has been very aggressive of late with a massive, well developed, strategy to shake up the market of healthcare. Their partnership with, the prestigious, Carnegie Melon and their patent that was issued for cancer treatment last month has the biotech and investing world paying attention. Take a look at the markets reaction from yesterday and today.
It appears all of the major positive indicators are pointing to a bullish run. The good news is, it just broke out of a massive pull back and is oversold creating massive value and upside potential..
As you can see from the press release above, TC BioPharm is making waves in the healthcare industry with its innovative approach to cancer treatment with cell therapy.
TC BioPharm was granted a European Patent causing the stock price to soar last month. Place TC BioPharm (NASDAQ:TCBP) on your watchlist today before it’s too late.
We have identified 6 catalysts!
#1 Catalyst – NEWS – Patent Issued for CANCER!
#2 Catalyst – The Chart Is Incredible!
#3 Catalyst – Innovative Therapies
#4 Catalyst – Strong Pipeline
#5 Catalyst – Experienced Management Team
#6 Catalyst – Strategic Partnerships: